{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:20:12Z","timestamp":1765527612836,"version":"3.48.0"},"reference-count":45,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Major Depressive Disorder (MDD) is a mood disorder classified as a persistent depressive mood and loss of interest lasting for more than two weeks and accompanied by a list of symptoms outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnostic criteria. MDD affects approximately 264 million people worldwide and is the most prevailing form of neuropsychiatric disorder. Owing to the probable hypothesized pathophysiology of MDD being an\u00a0outcome of abnormalities in the amino acid neurotransmitter system, including glutamate (the primary excitatory neurotransmitter) and\n                    <jats:italic>\u03b3<\/jats:italic>\n                    -aminobutyric acid (GABA), SAGE-217 (Zuranolone) is being evaluated as a possible therapeutic treatment for MDD. Zuranolone is a synthetic, neuroactive steroid (NAS) and positive allosteric modulator (PMA) of GABAA receptors, regulating both synaptic and extra-synaptic release of GABA. It is administered as a once-daily oral dose for 2\u00a0weeks due to its low-moderate clearance. A change in total HAM-D score from baseline was the primary end-point of all the trials. A phase II trial conducted to evaluate the efficacy and safety of Zuranolone (30\u00a0mg, once-daily dose), described a\u00a0significant reduction in total HAM-D score at day 14 and\u00a0reported the drug to be well tolerated with headache, dizziness, nausea, and somnolence as the most common adverse events (AE). Additional phase III trials were also conducted to evaluate similar outcomes, the interim topline results of which have been released. Consequently, this article attempts to briefly analyze the pharmacology of Zuranolone, review the available clinical data and outcomes regarding its use, and evaluate its place as a prospective novel therapy in the effective management of MDD.\n                  <\/jats:p>","DOI":"10.1515\/hmbci-2022-0042","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:08:16Z","timestamp":1677503296000},"page":"229-236","source":"Crossref","is-referenced-by-count":9,"title":["Zuranolone and its role in treating major depressive disorder: a narrative review"],"prefix":"10.1515","volume":"44","author":[{"given":"Muneeza","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine , Dow Medical College , Karachi , Pakistan"},{"name":"Department of Internal Medicine , Peshawar , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1100-101X","authenticated-orcid":false,"given":"Irfan","family":"Ullah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Kabir Medical College, Gandhara University , Peshawar , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mufaddal Najmuddin","family":"Diwan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Dow Medical College , Karachi , Pakistan"},{"name":"Department of Internal Medicine , Peshawar , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alifiya","family":"Aamir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Dow Medical College , Karachi , Pakistan"},{"name":"Department of Internal Medicine , Peshawar , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hashir Ali","family":"Awan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Dow Medical College , Karachi , Pakistan"},{"name":"Department of Internal Medicine , Peshawar , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Waris Durrani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Kabir Medical College, Gandhara University , Peshawar , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qudrat Ullah","family":"Qudrat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Kabir Medical College, Gandhara University , Peshawar , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-706X","authenticated-orcid":false,"given":"Sheikh","family":"Shoib","sequence":"additional","affiliation":[{"name":"Department of Psychiatry , Jawahar Lal Nehru Memorial Hospital , Srinagar , Kashmir , India"},{"name":"Sharda University , Greater Noida , Uttar Pradesh , India"},{"name":"Mind Wellness Center , Nawab Bazar , Srinagar , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"NHS, Department of Mental Health, Psychiatric Service for Diagnosis and Treatment , Hospital \u201cG. Mazzini\u201d , ASL 4 , Teramo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"2025121207204099212_j_hmbci-2022-0042_ref_001","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019;393(10190):e44]. Lancet. 2018;392:1789\u2013858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_002","doi-asserted-by":"crossref","unstructured":"Hecking, J, Davoudian, PA, Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders. Chronic Stress 2021;5. https:\/\/doi.org\/10.1177\/24705470211020446.","DOI":"10.1177\/24705470211020446"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_003","doi-asserted-by":"crossref","unstructured":"Rahman, S, Alzarea, S. Glial mechanisms underlying major depressive disorder: potential therapeutic opportunities. Prog Mol Biol Transl Sci 2019;167:159\u201378. https:\/\/doi.org\/10.1016\/bs.pmbts.2019.06.010.","DOI":"10.1016\/bs.pmbts.2019.06.010"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_004","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_005","doi-asserted-by":"crossref","unstructured":"Hasin, DS, Sarvet, AL, Meyers, JL, Saha, TD, Ruan, WJ, Stohl, M, et al.. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatr 2018;75:336\u201346. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4602.","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_006","doi-asserted-by":"crossref","unstructured":"Kennedy, SH, Ceniti, AK. Unpacking major depressive disorder: from classification to treatment selection. Can J Psychiatry 2018;63:308\u201313. https:\/\/doi.org\/10.1177\/0706743717748883.","DOI":"10.1177\/0706743717748883"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_007","doi-asserted-by":"crossref","unstructured":"Caspi, A, Sugden, K, Moffitt, TE, Taylor, A, Craig, IW, Harrington, H, et al.. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386\u20139. https:\/\/doi.org\/10.1126\/science.1083968.","DOI":"10.1126\/science.1083968"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_008","doi-asserted-by":"crossref","unstructured":"Kupferberg, A, Bicks, L, Hasler, G. Social functioning in major depressive disorder. Neurosci Biobehav Rev 2016;69:313\u201332. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.07.002.","DOI":"10.1016\/j.neubiorev.2016.07.002"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_009","doi-asserted-by":"crossref","unstructured":"Corfield, EC, Yang, Y, Martin, NG, Nyholt, DR. A continuum of genetic liability for minor and major depression. Transl Psychiatry 2017;7:e1131. https:\/\/doi.org\/10.1038\/tp.2017.99.","DOI":"10.1038\/tp.2017.99"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_010","doi-asserted-by":"crossref","unstructured":"Sullivan, PF, Neale, MC, Kendler, KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157:1552\u201362. https:\/\/doi.org\/10.1176\/appi.ajp.157.10.1552.","DOI":"10.1176\/appi.ajp.157.10.1552"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_011","unstructured":"Chiri\u0163\u0103, AL, Gheorman, V, Bondari, D, Rogoveanu, I. Current understanding of the neurobiology of major depressive disorder. Rom J Morphol Embryol 2015;56:651\u20138."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_012","unstructured":"American College of Physicians. ACP finds that cognitive behavioral therapy and second-generation antidepressants are similarly effective treatments for adults with major depressive disorder. American College of Physicians; 2021. https:\/\/www.acponline.org\/acp-newsroom\/acp-finds-that-cognitive-behavioral-therapy-and-second-generation-antidepressants-are-similarly [Accessed 24 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_013","doi-asserted-by":"crossref","unstructured":"Qaseem, A, Snow, V, Denberg, TD, Forciea, MA, Owens, DK. Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians [published correction appears in Ann Intern Med. 2009 Jan 20;150(2):148]. Ann Intern Med 2008;149:725\u201333. https:\/\/doi.org\/10.7326\/0003-4819-149-10-200811180-00007.","DOI":"10.7326\/0003-4819-149-10-200811180-00007"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_014","doi-asserted-by":"crossref","unstructured":"Gartlehner, G, Gaynes, BN, Hansen, RA, Thieda, P, DeVeaugh-Geiss, A, Krebs, EE, et al.. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734\u201350. https:\/\/doi.org\/10.7326\/0003-4819-149-10-200811180-00008.","DOI":"10.7326\/0003-4819-149-10-200811180-00008"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_015","doi-asserted-by":"crossref","unstructured":"Qaseem, A, Barry, MJ, Kansagara, D. Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;164:350\u20139. https:\/\/doi.org\/10.7326\/M15-2570.","DOI":"10.7326\/M15-2570"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_016","doi-asserted-by":"crossref","unstructured":"Arnaud, A, Suthoff, E, Stenson, K, Werneburg, B, Hodgkins, P, Bonthapally, V, et al.. Number needed to treat and number needed to harm analysis of the Zuranolone Phase II clinical trial results in major depressive disorder. J Affect Disord 2021;285:112\u20139. https:\/\/doi.org\/10.1016\/j.jad.2021.02.027.","DOI":"10.1016\/j.jad.2021.02.027"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_017","doi-asserted-by":"crossref","unstructured":"Althaus, AL, Ackley, MA, Belfort, GM, Gee, SM, Dai, J, Nguyen, DP, et al.. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator. Neuropharmacology 2020;181:108333. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108333.","DOI":"10.1016\/j.neuropharm.2020.108333"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_018","doi-asserted-by":"crossref","unstructured":"Hoffmann, E, Nomikos, GG, Kaul, I, Raines, S, Wald, J, Bullock, A, et al.. SAGE-217, A novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase I dose-finding studies. Clin Pharmacokinet 2020;59:111\u201320. https:\/\/doi.org\/10.1007\/s40262-019-00801-0.","DOI":"10.1007\/s40262-019-00801-0"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_019","doi-asserted-by":"crossref","unstructured":"M\u00f6hler, H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res 2006;326:505\u201316. https:\/\/doi.org\/10.1007\/s00441-006-0284-3.","DOI":"10.1007\/s00441-006-0284-3"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_020","doi-asserted-by":"crossref","unstructured":"Gunduz-Bruce, H, Silber, C, Kaul, I, Rothschild, AJ, Riesenberg, R, Sankoh, AJ, et al.. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 2019;381:903\u201311. https:\/\/doi.org\/10.1056\/NEJMoa1815981.","DOI":"10.1056\/NEJMoa1815981"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_021","doi-asserted-by":"crossref","unstructured":"Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56\u201362. https:\/\/doi.org\/10.1136\/jnnp.23.1.56.","DOI":"10.1136\/jnnp.23.1.56"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_022","doi-asserted-by":"crossref","unstructured":"Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382\u20139. https:\/\/doi.org\/10.1192\/bjp.134.4.382.","DOI":"10.1192\/bjp.134.4.382"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_023","unstructured":"Busner, J, Targum, SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 2007;4:28\u201337."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_024","doi-asserted-by":"crossref","unstructured":"Hoddes, E, Zarcone, V, Smythe, H, Phillips, R, Dement, WC. Quantification of sleepiness: a new approach. Psychophysiology 1973;10:431\u20136. https:\/\/doi.org\/10.1111\/j.1469-8986.1973.tb00801.x.","DOI":"10.1111\/j.1469-8986.1973.tb00801.x"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_025","doi-asserted-by":"crossref","unstructured":"Posner, K, Brown, GK, Stanley, B, Brent, DA, Yershova, KV, Oquendo, MA, et al.. The columbia\u2013suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatr 2011;168:1266\u201377. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10111704.","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_026","unstructured":"Sage, B. Therapeutics reports topline results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in major depressive disorder [Internet]. Cambridge: Businesswire; 2019. https:\/\/www.businesswire.com\/news\/home\/20191205005375\/en\/Sage-TherapeuticsReports-Topline-Results-Pivotal-Phase [Accessed 26 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_027","doi-asserted-by":"crossref","unstructured":"Clayton, A, Lasser, R, Nandy, I, Sankoh, AJ, Campbell, A, Werneburg, B, et al.. A phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult patients with major depressive disorder. Biol Psychiatr 2020;87:S86. https:\/\/doi.org\/10.1016\/J.BIOPSYCH.2020.02.242.","DOI":"10.1016\/j.biopsych.2020.02.242"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_028","unstructured":"National Institute of Health. A study to evaluate the efficacy of SAGE-217 in the treatment of adult subjects with major depressive disorder. NIH, U.S. National Library of Medicine; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03672175 [Accessed 26 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_029","doi-asserted-by":"crossref","unstructured":"Walkery, A, Leader, LD, Cooke, E, VandenBerg, A. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. Drug Des Dev Ther 2021;15:3017\u201326. https:\/\/doi.org\/10.2147\/DDDT.S240856.","DOI":"10.2147\/DDDT.S240856"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_030","unstructured":"National Institute of Health. A study to evaluate SAGE-217 in adult participants with Major Depressive Disorder (MDD). NIH, U.S. National Library of Medicine; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03864614 [Accessed 27 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_031","doi-asserted-by":"crossref","unstructured":"Cutler, A, Aaronson, ST, Mattingly, GW, Wilkinson, ST, Lasser, R, Nandy, I, et al.. Zuranolone in major depressive disorder: interim safety results from a phase 3, open-label, longitudinal study. Biol Psychiatr 2021;89:S161. https:\/\/doi.org\/10.1016\/J.BIOPSYCH.2021.02.413.","DOI":"10.1016\/j.biopsych.2021.02.413"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_032","unstructured":"Sage, B. Therapeutics announces positive interim, Topline Zuranolone Safety and Tolerability Data from open-label SHORELINE Study in patients with MDD [Internet]. Cambridge: Businesswire; 2020. https:\/\/www.businesswire.com\/news\/home\/20201015005330\/en\/Sage-Therapeutics-Announces-Positive-Interim-Topline-Zuranolone-Safety-and-Tolerability-Data-from-Open-Label-SHORELINE-Study-in-Patients-with-MDD [Accessed 27 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_033","unstructured":"National Institute of Health. A study to evaluate the efficacy of Sage-217 in the treatment of adult participants with Major Depressive Disorder (MDD). NIH, U.S. National Library of Medicine; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04442490 [Accessed 27 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_034","unstructured":"National Institute of Health. A comparative study of Sage-217 plus an Antidepressant (ADT) versus placebo plus an ADT in adults with major depressive disorder. NIH, U.S. National Library of Medicine; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04476030 [Accessed 27 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_035","doi-asserted-by":"crossref","unstructured":"Wilkinson, ST, Sanacora, G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems. Drug Discov Today 2019;24:606\u201315. https:\/\/doi.org\/10.1016\/j.drudis.2018.11.007.","DOI":"10.1016\/j.drudis.2018.11.007"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_036","doi-asserted-by":"crossref","unstructured":"Sanacora, G, Zarate, CA, Krystal, JH, Manji, HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426\u201337. https:\/\/doi.org\/10.1038\/nrd2462.","DOI":"10.1038\/nrd2462"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_037","unstructured":"FDA News Release. FDA approves first treatment for postpartum depression. Food and Drug Administration, United States of America; 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-post-partum-depression [Accessed 27 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_038","doi-asserted-by":"crossref","unstructured":"Ali, M, Aamir, A, Diwan, MN, Awan, HA, Ullah, I, Irfan, M, et al.. Treating postpartum depression: what do we know about brexanolone? Diseases 2021;9:52. https:\/\/doi.org\/10.3390\/diseases9030052.","DOI":"10.3390\/diseases9030052"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_039","unstructured":"Psych Congress. Novel depression drug awarded FDA\u2019s breakthrough therapy designation. Psych Congress Network; 2018. https:\/\/www.hmpgloballearningnetwork.com\/site\/pcn\/article\/novel-depression-drug-awarded-fdas-breakthrough-therapy-designation [Accessed 27 Aug 2021]."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_040","doi-asserted-by":"crossref","unstructured":"Ogawa, Y, Takeshima, N, Hayasaka, Y, Tajika, A, Watanabe, N, Streiner, D, et al.. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev 2019;6:CD001026. https:\/\/doi.org\/10.1002\/14651858.CD001026.pub2.","DOI":"10.1002\/14651858.CD001026.pub2"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_041","doi-asserted-by":"crossref","unstructured":"Rosenblat, JD. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 2019;381:2178\u20139. https:\/\/doi.org\/10.1056\/NEJMc1913170.","DOI":"10.1056\/NEJMc1913170"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_042","doi-asserted-by":"crossref","unstructured":"Ten Doesschate, F, van Waarde, JA, van Wingen, GA. Non-superiority of zuranolone (SAGE-217) at the longer-term. J Affect Disord 2021;291:329\u201330. https:\/\/doi.org\/10.1016\/j.jad.2021.05.015.","DOI":"10.1016\/j.jad.2021.05.015"},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_043","unstructured":"Deligiannidis, KM, Lasser, R, Gunduz-Bruce, H, Doherty, J, Jonas, J, Li, S, et al.. The ROBIN trial, a phase 3, double-blind, placebo-controlled trial of zuranolone in postpartum depression. In: Poster presented at: psych Congress 2020 Virtual Experience. Virtual 2020."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_044","unstructured":"Gunduz-Bruce, H, Lasser, R, Nandy, I, Sankoh, AJ, Jonas, J, Doherty, J, et al.. Open-label, Phase 2 trial of the oral neuroactive steroid GABAA receptor positive allosteric modulator zuranolone in bipolar disorder I and II. In: Poster presented at: psych Congress 2020 Virtual Experience. Virtual; 2020."},{"key":"2025121207204099212_j_hmbci-2022-0042_ref_045","unstructured":"World Health Organization. Depression\u00a0\u2013 fact sheet. Geneva: World Health Organization; 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression [Accessed 27 Aug 2021]."}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2022-0042\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2022-0042\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:15:35Z","timestamp":1765527335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2022-0042\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,27]]},"published-print":{"date-parts":[[2023,6,30]]}},"alternative-id":["10.1515\/hmbci-2022-0042"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2022-0042","relation":{},"ISSN":["1868-1891"],"issn-type":[{"type":"electronic","value":"1868-1891"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}